Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
University of Health Sciences, Lahore, Pakistan.
Sci Rep. 2021 Apr 21;11(1):8632. doi: 10.1038/s41598-021-87974-6.
Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not known. We recruited male healthy controls and patients with CHF and COPD (n = 81-87/group), aged 55-74 years. Sarcopenia was clinically identified based on hand-grip strength, appendicular skeletal muscle index and physical capacity as recommended by the European working group for sarcopenia. The serum levels of amino-terminal pro-peptide of type-III procollagen, c-terminal agrin fragment-22, osteonectin, irisin, fatty acid-binding protein-3 and macrophage migration inhibitory factor were significantly different between healthy controls and patients with CHF and COPD. Risk scores for individual biomarkers were calculated by logistic regressions and combined into a cumulative risk score. The median cutoff value of 3.86 was used to divide subjects into high- and low-risk groups for sarcopenia with the area under the curve of 0.793 (95% CI = 0.738-0.845, p < 0.001). A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.
随着年龄的增长，肌肉质量和力量的丧失，即称为肌肉减少症，在几种合并症中加速，包括慢性心力衰竭（CHF）和慢性阻塞性肺疾病（COPD）。然而，目前还不知道有效的循环生物标志物来准确诊断和评估肌肉减少症。我们招募了年龄在 55-74 岁的男性健康对照者和 CHF 及 COPD 患者（每组 81-87 人）。根据欧洲肌肉减少症工作组的建议，通过握力、四肢骨骼肌指数和身体能力来临床确定肌肉减少症。III 型前胶原氨基末端肽、C 端聚集素片段-22、骨粘连蛋白、鸢尾素、脂肪酸结合蛋白-3 和巨噬细胞移动抑制因子的血清水平在健康对照者和 CHF 及 COPD 患者之间有显著差异。通过逻辑回归计算个体生物标志物的风险评分，并将其组合成累积风险评分。中位数截断值为 3.86，用于将受试者分为肌肉减少症高风险和低风险组，曲线下面积为 0.793（95%CI=0.738-0.845，p<0.001）。高风险组的临床肌肉减少症发生率明显更高。总之，该生物标志物组合可作为早期诊断和评估肌肉减少症的有效工具。
